Doxofylline

Research use only, not for human use.

Doxofylline is a phosphodiesterase inhibitor and a xanthine derivative drug for asthma.

Doxofylline is a phosphodiesterase inhibitor and a xanthine derivative drug for asthma.(In Vitro):Doxofylline (5, 10 μM; 48 h) shows potent protection against LPS-induced epithelial inflammation by reducing PGE2, NO release, and decreasing mitochondrial ROS generation in 16HBE cells.Doxofylline (5, 10 μM; 48 h) suppresses LPS-induced expression of NADPH oxidase subunits and TXNIP 16HBE cells.Doxofylline (5, 10 μM; 48 h) inhibits LPS-induced NLRP3 inflammasome activation and secretion of IL-1b and IL-18, as well as mitigates LPS-mediated SIRT1 reduction.Doxofylline (0.1-10 μM; 15 min) significantly reduces fMLP-induced leukocyte migration in BM cells (fMLP: Formyl-Methionyl-Leucyl-Phenylalanine).(In Vivo):Doxofylline (0.3, 1 mg/kg; i.p.; single) inhibits LPS-induced inflammation in the lungs of mice.Doxofylline (0.3 mg/kg; i.p.; pre-treat; single) notably reduces the adhesion of cells to the vascular tissue and surpresses the expression of LPS-induced ICAM-1 in vivo.

Doxofylline (5, 10 μM; 48 h) shows potent protection against LPS-induced epithelial inflammation by reducing PGE2, NO release, and decreasing mitochondrial ROS generation in 16HBE cells.Doxofylline (5, 10 μM; 48 h) suppresses LPS-induced expression of NADPH oxidase subunits and TXNIP 16HBE cells.Doxofylline (5, 10 μM; 48 h) inhibits LPS-induced NLRP3 inflammasome activation and secretion of IL-1b and IL-18, as well as mitigates LPS-mediated SIRT1 reduction.Doxofylline (0.1-10 μM; 15 min) significantly reduces fMLP-induced leukocyte migration in BM cells (fMLP: Formyl-Methionyl-Leucyl-Phenylalanine). Cell Viability Assay Cell Line:16HBE cells Concentration:5, 10 μM Incubation Time:48 h Result:Weakened LPS-induced NO and PGE2 in a dose-dependent manner.Exerted dose-dependent inhibition on LPS-induced mitochondrial ROS production and NADPH oxidase subunits expression.Suppressed LPS-induced TXNIP expression and NLRP3 inflammasome activation at the protein level in a dose-dependent manner.Inhibited LPS-induced secretion of IL-1b and IL-18.Cell Viability Assay Cell Line:BM cells (from naive mice)Concentration:0.1-10 μMIncubation Time:15 min (pretreat)Result:Notably surpressed positive migration of BM cells in response to fMLP.

Doxofylline (0.3, 1 mg/kg; i.p.; single) inhibits LPS-induced inflammation in the lungs of mice.Doxofylline (0.3 mg/kg; i.p.; pre-treat; single) notably reduces the adhesion of cells to the vascular tissue and surpresses the expression of LPS-induced ICAM-1 in vivo. Animal Model:Male BALB/c mice (6 to 8-week-old).Dosage:0.3, 1 mg/kg Administration:Intraperitoneal injection; single.Result:Significantly inhibited the migration of neutrophils and the release of IL-6 and TNF-a into the lung lumen.Increased the bone marrow leukocyte numbers to levels similar to those seen in the saline-treated group.Notably reduced the number of circulating leukocytes in comparison to LPS-treated mice.Significantly reduced accumulation of neutrophils in the peribronchial area.Animal Model:Male BALB/c mice (6 to 8-week-old).Dosage:0.3 mg/kg Administration:Intraperitoneal injection; pre-treat; single.Result:Significantly reduced the adhesion of cells to the vascular tissue, but not the rolling of cells along the vessel wall in mice.Significantly reduced the expression of ICAM-1 induced by LPS.

Doxofylline | Ansimar | ABC-12-3 | ABC-1213 | ABC 1213 | ALT 07 | DO 309

Angiogenesis

PDE

PDE

Inflammation/Immunology

——

69975-86-6

266.26

C11H14N4O4

>98% (HPLC)

Ethanol: 2 mg/mL (7.51 mM); Water: 24 mg/mL (90.14 mM); DMSO: 53 mg/mL (199.06 mM)

O=C(N1C)N(C)C2=C(N(CC3OCCO3)C=N2)C1=O

7-((1,3-dioxolan-2-yl)methyl)-1,3-dimethyl-3,7-dihydro-1H-purine-2,6-dione

(-20℃)

With Ice Pack

≥ 2 years